Profile of the patient’s serum cytokines
| Cytokine (pg/mL) | LLQ | Before treatment* | At remission† | Cytokine (pg/mL) | LLQ | Before treatment* | At remission† |
| IL-1β | 0.6 | 5.0 | ND | Eotaxin | 0.1 | 67.1 | 97.8 |
| IL-1ra | 15.5 | 860.2 | ND | FGF | 3.4 | 34.2 | ND |
| IL-2 | 2.1 | ND | ND | G-CSF | 6.0 | 63.1 | ND |
| IL-4 | 1.1 | ND | ND | GM-CSF | 0.4 | ND | ND |
| IL-5 | 0.1 | 5.5 | ND | IFN-γ | 0.3 | ND | ND |
| IL-6 | 0.5 | 15.5 | ND | IP-10 | 3.5 | 6884.3 | 230.9 |
| IL-7 | 2.2 | 20.6 | ND | MCP-1 | 0.4 | 16.2 | 16.5 |
| IL-8 | 1.0 | 17.8 | 2.7 | MIP-1α | 0.04 | 2.3 | ND |
| IL-9 | 2.3 | 9.3 | 3.1 | PDGF | 4.6 | 10 537 | 2006 |
| IL-10 | 1.7 | ND | ND | MIP-1β | 0.5 | 86.8 | 61.0 |
| IL-12 (p70) | 1.1 | ND | ND | RANTES | 3.7 | 4014.3 | 3265.0 |
| IL-13 | 0.3 | ND | ND | TNF-α | 3.2 | 32.3 | 9.3 |
| IL-15 | 33.7 | ND | ND | VEGF | 13.1 | 249.5 | ND |
| IL-17 | 1.8 | ND | ND |
*At the onset of neurological symptoms.
†At the remission phase after 8 months with glucocorticoid treatment.
FGF, fibroblast growth factor; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte macrophage colony-stimulating factor; IFN, interferon; IL, interleukin; IP, interferon-inducible protein; LLQ, lower limit of quantification; MCP, monocyte chemotactic protein; MIP, macrophage inflammatory protein; ND, not determined; PDGF, platelet-derived growth factor; ra, receptor antagonist; RANTES, regulated on activation normal T-cell expressed and secreted; TNF, tumour necrosis factor; VEGF, vascular endothelial growth factor.